Document Detail


HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque.
MedLine Citation:
PMID:  12182229     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are greatly contributed to the treatment of hypercholesterolemia, and constitute an important part of comprehensive strategies for the treatment of cardiovascular disease in the 21st century. Particularly, a strategy for preventing acute coronary syndrome (ACS), the most important complication of hyperlipidemia, is urgently needed. Recent research has revealed a new mechanism of prevention of coronary heart disease by statins: they not only lowered cholesterol level as previously reported, but also contribute directly to plaque stabilization. Among many statins recently marketed, some act directly onto the blood vessel wall to stabilize plaques already formed (so-called vascular statins), while statins are originally classified as chemical or non-chemical. At the same time, reports on pleiotropic activities of statins, including improvement of osteoporosis, have accumulated to suggest an extended role of statins, not merely as a hypolipidemic agent but also possibly an anti-arteriosclerotic/anti-aging drug. This article reviews the direct action of statins on the blood vessel wall, with reference to classification of statins based on difference in action on the blood vessel wall (hepatic statins vs. vascular statins).
Authors:
Ryuichi Morishita; Naruya Tomita; Toshio Ogihara
Related Documents :
19091169 - The role of cholesterol and statins in stroke.
20027659 - Statin therapy decreases myocardial function as evaluated via strain imaging.
12532169 - Statins in acute coronary syndromes.
11122689 - Recent developments in the treatment of hypertriglyceridemia.
9012659 - Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estroge...
8902159 - Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acut...
16564179 - The sequence of regional ventricular motion.
23932859 - Intrapulmonary shear stress enhancement: a new therapeutic approach in acute myocardial...
9313599 - Congestive heart failure in patients with coronary artery disease: the gender paradox.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current drug targets     Volume:  3     ISSN:  1389-4501     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-08-16     Completed Date:  2003-02-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  379-85     Citation Subset:  IM    
Affiliation:
Department of Geriatric Medicine, Osaka University, Graduate School of Medicine, Suita, Japan. morishit@geriat.med.osaka-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / pharmacology,  therapeutic use*
Biological Availability
Cardiovascular Diseases / drug therapy*,  pathology
Coronary Artery Disease / drug therapy,  pathology
Coronary Vessels / drug effects,  pathology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use*
Hypercholesterolemia / drug therapy,  pathology
Muscle, Smooth, Vascular / drug effects,  pathology
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic strategies for hepatitis B virus-associated hepatocellular carcinoma.
Next Document:  Computational function assignment for potential drug targets: from single genes to cellular systems.